tenofovir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antivirals phosphonic acid derivatives	2592	147127-20-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: tenofovir hydrate tenofovir tenefovir	An adenine analog REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B. It is used to treat HIV INFECTIONS and CHRONIC HEPATITIS B, in combination with other ANTIVIRAL AGENTS, due to the emergence of ANTIVIRAL DRUG RESISTANCE when it is used alone. Molecular weight: 287.22 Formula: C9H14N5O4P CLOGP: -1.16 LIPINSKI: 0 HAC: 9 HDO: 3 TPSA: 136.38 ALOGS: -2.19 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

tenofovir hydrate
tenofovir
tenefovir

An adenine analog REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B. It is used to treat HIV INFECTIONS and CHRONIC HEPATITIS B, in combination with other ANTIVIRAL AGENTS, due to the emergence of ANTIVIRAL DRUG RESISTANCE when it is used alone.

Molecular weight: 287.22
Formula: C9H14N5O4P
CLOGP: -1.16
LIPINSKI: 0
HAC: 9
HDO: 3
TPSA: 136.38
ALOGS: -2.19
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BA (Bioavailability)	25 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.83 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	3.10 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.93 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	5.80 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Nov. 5, 2009	FDA	HETERO DRUGS LTD
March 25, 2004	PMDA	Japan Tobacco Inc.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Maternal exposure during pregnancy	198.52	30.95	110	2191	159668	50443155
Drug resistance	138.18	30.95	46	2255	18943	50583880
Rebound effect	130.31	30.95	30	2271	3159	50599664
Virologic failure	110.10	30.95	23	2278	1541	50601282
Drug interaction	102.09	30.95	79	2222	199542	50403281
Foetal exposure during pregnancy	100.39	30.95	40	2261	27319	50575504
Immune reconstitution inflammatory syndrome	95.07	30.95	26	2275	5490	50597333
Fanconi syndrome acquired	91.21	30.95	18	2283	905	50601918
Viral mutation identified	86.55	30.95	19	2282	1610	50601213
Exposure during pregnancy	82.34	30.95	57	2244	120958	50481865
Hepatitis B	72.29	30.95	19	2282	3447	50599376
Premature delivery	54.84	30.95	25	2276	23638	50579185
Pathogen resistance	54.47	30.95	17	2284	5672	50597151
Birth mark	49.23	30.95	8	2293	130	50602693
Congenital umbilical hernia	49.08	30.95	9	2292	304	50602519
Fanconi syndrome	48.05	30.95	11	2290	1125	50601698
Abortion spontaneous	46.70	30.95	27	2274	41745	50561078
Blood HIV RNA increased	44.03	30.95	9	2292	540	50602283
Immune reconstitution inflammatory syndrome associated tuberculosis	42.21	30.95	8	2293	324	50602499
Autoimmune hepatitis	42.11	30.95	15	2286	7504	50595319
Renal tubular dysfunction	41.28	30.95	8	2293	365	50602458
Hypophosphataemic osteomalacia	40.64	30.95	7	2294	164	50602659
Glycosuria	37.85	30.95	9	2292	1085	50601738
Ergot poisoning	37.06	30.95	6	2295	95	50602728
Glucocorticoids increased	35.46	30.95	6	2295	126	50602697
Stillbirth	33.80	30.95	12	2289	5940	50596883
Treatment noncompliance	32.39	30.95	19	2282	30131	50572692
Abortion induced	31.93	30.95	13	2288	9331	50593492
Hereditary optic atrophy	30.99	30.95	4	2297	10	50602813

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Immune reconstitution inflammatory syndrome	227.71	22.88	73	4536	7729	29562189
Psychiatric decompensation	150.66	22.88	37	4572	1467	29568451
Retinal toxicity	149.00	22.88	29	4580	375	29569543
Depression suicidal	145.25	22.88	35	4574	1280	29568638
Mitochondrial toxicity	137.96	22.88	38	4571	2373	29567545
Tearfulness	137.66	22.88	35	4574	1601	29568317
Lipodystrophy acquired	137.39	22.88	40	4569	3054	29566864
Progressive external ophthalmoplegia	134.96	22.88	33	4576	1284	29568634
Drug interaction	123.22	22.88	152	4457	197233	29372685
Acquired gene mutation	121.21	22.88	30	4579	1228	29568690
Hepatitis B	118.63	22.88	41	4568	5456	29564462
Fanconi syndrome acquired	100.62	22.88	28	4581	1814	29568104
Eyelid ptosis	90.33	22.88	33	4576	5153	29564765
Foetal exposure during pregnancy	86.60	22.88	58	4551	33809	29536109
Depressive symptom	84.24	22.88	24	4585	1693	29568225
Drug resistance	83.26	22.88	48	4561	21492	29548426
Paranoia	79.15	22.88	36	4573	9841	29560077
Psychomotor skills impaired	77.96	22.88	25	4584	2636	29567282
Pathogen resistance	76.01	22.88	33	4576	8083	29561835
Psychotic disorder	72.44	22.88	43	4566	20311	29549607
Hepatic failure	71.16	22.88	50	4559	31462	29538456
Diplopia	62.78	22.88	34	4575	13484	29556434
Gene mutation	62.28	22.88	17	4592	1024	29568894
Ophthalmoplegia	50.07	22.88	16	4593	1666	29568252
Hepatitis B reactivation	46.92	22.88	18	4591	3211	29566707
Suicidal ideation	45.56	22.88	40	4569	34676	29535242
Congenital umbilical hernia	43.95	22.88	10	4599	283	29569635
Birth mark	43.54	22.88	9	4600	160	29569758
Drug-induced liver injury	43.45	22.88	32	4577	21623	29548295
Adrenal suppression	42.86	22.88	11	4598	521	29569397
Night blindness	41.14	22.88	9	4600	212	29569706
Psychomotor retardation	37.63	22.88	15	4594	2961	29566957
Superior mesenteric artery syndrome	37.51	22.88	7	4602	71	29569847
Nephropathy toxic	36.36	22.88	22	4587	10734	29559184
BRASH syndrome	32.62	22.88	7	4602	150	29569768
Fanconi syndrome	30.93	22.88	11	4598	1587	29568331
Mitochondrial myopathy	30.80	22.88	7	4602	197	29569721
Hepatocellular carcinoma	30.72	22.88	17	4592	7021	29562897
Anxiety	29.65	22.88	50	4559	85315	29484603
Osteomalacia	28.84	22.88	9	4600	867	29569051
Renal tubular dysfunction	25.89	22.88	7	4602	406	29569512
Portal hypertension	25.70	22.88	12	4597	3474	29566444
Brachydactyly	25.57	22.88	6	4603	195	29569723
Osteoporotic fracture	23.74	22.88	8	4601	983	29568935
Hepatic fibrosis	23.37	22.88	11	4598	3241	29566677
Depression	23.33	22.88	45	4564	85102	29484816

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Immune reconstitution inflammatory syndrome	340.42	20.91	100	6352	12370	64479910
Hepatitis B	202.02	20.91	60	6392	7685	64484595
Drug interaction	188.81	20.91	205	6247	361878	64130402
Drug resistance	158.52	20.91	75	6377	35027	64457253
Progressive external ophthalmoplegia	149.24	20.91	33	6419	1294	64490986
Retinal toxicity	149.17	20.91	33	6419	1297	64490983
Psychiatric decompensation	148.79	20.91	37	6415	2426	64489854
Mitochondrial toxicity	145.33	20.91	37	6415	2669	64489611
Fanconi syndrome acquired	144.40	20.91	36	6416	2385	64489895
Depression suicidal	138.64	20.91	35	6417	2440	64489840
Acquired gene mutation	136.00	20.91	33	6419	1953	64490327
Pathogen resistance	135.70	20.91	50	6402	12493	64479787
Lipodystrophy acquired	135.29	20.91	38	6414	3989	64488291
Maternal exposure during pregnancy	119.35	20.91	89	6363	95795	64396485
Tearfulness	116.61	20.91	35	6417	4638	64487642
Rebound effect	102.18	20.91	32	6420	4885	64487395
Viral mutation identified	87.55	20.91	26	6426	3320	64488960
Eyelid ptosis	81.48	20.91	32	6420	9493	64482787
Psychomotor skills impaired	79.79	20.91	25	6427	3820	64488460
Paranoia	77.02	20.91	36	6416	16316	64475964
Fanconi syndrome	76.77	20.91	22	6430	2479	64489801
Psychotic disorder	76.63	20.91	46	6406	34532	64457748
Depressive symptom	75.95	20.91	25	6427	4471	64487809
Gene mutation	71.53	20.91	20	6432	2062	64490218
Hepatitis B reactivation	69.97	20.91	24	6428	4865	64487415
Hepatic failure	65.69	20.91	50	6402	55344	64436936
Virologic failure	61.48	20.91	20	6432	3446	64488834
Nephropathy toxic	57.03	20.91	30	6422	17484	64474796
CSF HIV escape syndrome	53.11	20.91	11	6441	314	64491966
Diplopia	52.63	20.91	33	6419	26732	64465548
Drug-induced liver injury	52.10	20.91	41	6411	47602	64444678
Adrenal suppression	46.74	20.91	13	6439	1314	64490966
Ophthalmoplegia	45.53	20.91	15	6437	2687	64489593
Night blindness	43.98	20.91	10	6442	445	64491835
Glycosuria	41.01	20.91	13	6439	2061	64490219
Renal tubular dysfunction	39.69	20.91	10	6442	690	64491590
Psychomotor retardation	39.53	20.91	16	6436	5127	64487153
Hypophosphataemia	39.00	20.91	22	6430	14698	64477582
Immune reconstitution inflammatory syndrome associated tuberculosis	38.71	20.91	10	6442	763	64491517
Suicidal ideation	38.48	20.91	40	6412	66502	64425778
Blood HIV RNA increased	36.52	20.91	11	6441	1473	64490807
Superior mesenteric artery syndrome	35.20	20.91	7	6445	162	64492118
Hepatocellular carcinoma	34.98	20.91	17	6435	8386	64483894
Exposure during pregnancy	33.40	20.91	40	6412	77635	64414645
Osteomalacia	32.90	20.91	10	6442	1381	64490899
Hepatic encephalopathy	31.74	20.91	22	6430	21044	64471236
Mitochondrial myopathy	31.46	20.91	7	6445	282	64491998
Foetal exposure during pregnancy	31.25	20.91	13	6439	4463	64487817
Hypophosphataemic osteomalacia	31.13	20.91	7	6445	296	64491984
Hereditary optic atrophy	31.05	20.91	5	6447	32	64492248
Glucocorticoids increased	30.73	20.91	6	6446	126	64492154
Ergot poisoning	30.29	20.91	6	6446	136	64492144
Portal hypertension	30.23	20.91	14	6438	6205	64486075
BRASH syndrome	29.61	20.91	7	6445	370	64491910
Hepatic cirrhosis	29.53	20.91	23	6429	26275	64466005
Renal impairment	26.47	20.91	48	6404	134969	64357311
Renal tubular necrosis	26.28	20.91	20	6432	22090	64470190
Meningitis cryptococcal	25.34	20.91	10	6442	2999	64489281
Treatment noncompliance	24.87	20.91	26	6426	43456	64448824
Premature delivery	24.74	20.91	18	6434	18571	64473709
Autoimmune hepatitis	23.85	20.91	14	6438	10070	64482210
Unmasking of previously unidentified disease	23.23	20.91	8	6444	1639	64490641
HIV infection	22.97	20.91	7	6445	975	64491305
Cerebral toxoplasmosis	22.42	20.91	8	6444	1818	64490462
Hepatic fibrosis	22.41	20.91	11	6441	5541	64486739
Malaise	22.40	20.91	6	6446	396241	64096039
Abortion spontaneous	21.96	20.91	19	6433	25124	64467156
Cushingoid	21.87	20.91	12	6440	7591	64484689
Oligohydramnios	21.56	20.91	9	6443	3115	64489165
Acute hepatic failure	21.34	20.91	19	6433	26093	64466187
Abortion induced	20.95	20.91	11	6441	6377	64485903
Vascular stent thrombosis	20.92	20.91	9	6443	3355	64488925

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
MeSH PA	D019380	Anti-HIV Agents
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D044966	Anti-Retroviral Agents
MeSH PA	D000998	Antiviral Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D019384	Nucleic Acid Synthesis Inhibitors
MeSH PA	D018894	Reverse Transcriptase Inhibitors
CHEBI has role	CHEBI:36044	antiviral drugs
CHEBI has role	CHEBI:49103	drug metabolites
CHEBI has role	CHEBI:53756	reverse transcriptase inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Chronic type B viral hepatitis	indication	61977001
Human immunodeficiency virus infection	indication	86406008	DOID:526
Coronavirus infection	off-label use	186747009
Prevention of HIV Infection after Exposure	off-label use
Osteomalacia	contraindication	4598005	DOID:10573
Hypophosphatemia	contraindication	4996001
Suicidal thoughts	contraindication	6471006
Hypercholesterolemia	contraindication	13644009
Torsades de pointes	contraindication	31722008
Depressive disorder	contraindication	35489007
Fanconi syndrome	contraindication	40488004	DOID:1062
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Aggressive behavior	contraindication	61372001
Kidney disease	contraindication	90708001	DOID:557
Lactic acidosis	contraindication	91273001	DOID:3650
Prolonged QT interval	contraindication	111975006
Chronic hepatitis C	contraindication	128302006
Seizure disorder	contraindication	128613002
Liver function tests abnormal	contraindication	166603001
Paranoid disorder	contraindication	191667009
Steatosis of liver	contraindication	197321007
Mania	contraindication	231494001
Disease of liver	contraindication	235856003	DOID:409
Pathological fracture	contraindication	268029009
Pregnancy, function	contraindication	289908002
Hypertriglyceridemia	contraindication	302870006
Severe depression	contraindication	310497006
Osteopenia	contraindication	312894000
Breastfeeding (mother)	contraindication	413712001
Obesity	contraindication	414916001	DOID:9970
Congenital long QT syndrome	contraindication	442917000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	0.23	acidic
pKa2	4.92	acidic
pKa3	4.28	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	UniProt	Type	Activity value (-log[M])	Bioact source
Reverse transcriptase/RNaseH	Enzyme	Q72547_9HIV1	IC50	6.42	CHEMBL
Reverse transcriptase	Enzyme	Q9WKE8_9HIV1	IC50	6.42	CHEMBL
Capsid protein	Unclassified	Q03732_HBV	EC50	6.62	CHEMBL

External reference:

ID	Source
4021279	VUID
N0000148716	NUI
D06074	KEGG_DRUG
4021279	VANDF
C0384228	UMLSCUI
CHEBI:63625	CHEBI
TFO	PDB_CHEM_ID
CHEMBL483	ChEMBL_ID
CHEMBL3989702	ChEMBL_ID
CHEMBL1486	ChEMBL_ID
DB14126	DRUGBANK_ID
D000068698	MESH_DESCRIPTOR_UI
464205	PUBCHEM_CID
10948	IUPHAR_LIGAND_ID
99YXE507IL	UNII
117466	RXNORM
d04774	MMSL
009357	NDDF
395264002	SNOMEDCT_US
422091007	SNOMEDCT_US
206184-49-8	SECONDARY_CAS_RN

Pharmaceutical products:

None